171 related articles for article (PubMed ID: 32762134)
1. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?
Yesil Cinkir H; Colakoglu Er H
Asia Pac J Clin Oncol; 2020 Oct; 16(5):e223-e227. PubMed ID: 32762134
[TBL] [Abstract][Full Text] [Related]
2. The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective.
Sütcüoğlu O; Erdal ZS; Akdoğan O; Çeltikçi E; Özdemir N; Özet A; Uçar M; Yazıcı O
Turk J Med Sci; 2023 Feb; 53(1):413-419. PubMed ID: 36945944
[TBL] [Abstract][Full Text] [Related]
3. Predictive Value of Temporal Muscle Thickness Measurements on Cranial Magnetic Resonance Images in the Prognosis of Patients With Primary Glioblastoma.
Liu F; Xing D; Zha Y; Wang L; Dong W; Li L; Gong W; Hu L
Front Neurol; 2020; 11():523292. PubMed ID: 33304303
[No Abstract] [Full Text] [Related]
4. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
An G; Ahn S; Park JS; Jeun SS; Hong YK
J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
[TBL] [Abstract][Full Text] [Related]
5. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.
Furtner J; Berghoff AS; Albtoush OM; Woitek R; Asenbaum U; Prayer D; Widhalm G; Gatterbauer B; Dieckmann K; Birner P; Aretin B; Bartsch R; Zielinski CC; Schöpf V; Preusser M
Eur Radiol; 2017 Aug; 27(8):3167-3173. PubMed ID: 28050694
[TBL] [Abstract][Full Text] [Related]
6. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
Furtner J; Genbrugge E; Gorlia T; Bendszus M; Nowosielski M; Golfinopoulos V; Weller M; van den Bent MJ; Wick W; Preusser M
Neuro Oncol; 2019 Dec; 21(12):1587-1594. PubMed ID: 31369680
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.
Muglia R; Simonelli M; Pessina F; Morenghi E; Navarria P; Persico P; Lorenzi E; Dipasquale A; Grimaldi M; Scorsetti M; Santoro A; Politi LS
Eur Radiol; 2021 Jun; 31(6):4079-4086. PubMed ID: 33201284
[TBL] [Abstract][Full Text] [Related]
8. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.
Furtner J; Berghoff AS; Schöpf V; Reumann R; Pascher B; Woitek R; Asenbaum U; Pelster S; Leitner J; Widhalm G; Gatterbauer B; Dieckmann K; Höller C; Prayer D; Preusser M
J Neurooncol; 2018 Oct; 140(1):173-178. PubMed ID: 30008154
[TBL] [Abstract][Full Text] [Related]
9. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
Chaddad A; Sabri S; Niazi T; Abdulkarim B
Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
[TBL] [Abstract][Full Text] [Related]
10. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
[TBL] [Abstract][Full Text] [Related]
11. A novel radiographic marker of sarcopenia with prognostic value in glioblastoma.
Huq S; Khalafallah AM; Ruiz-Cardozo MA; Botros D; Oliveira LAP; Dux H; White T; Jimenez AE; Gujar SK; Sair HI; Pillai JJ; Mukherjee D
Clin Neurol Neurosurg; 2021 Aug; 207():106782. PubMed ID: 34186275
[TBL] [Abstract][Full Text] [Related]
12. Survival Analysis of Glioblastoma Multiforme.
Witthayanuwat S; Pesee M; Supaadirek C; Supakalin N; Thamronganantasakul K; Krusun S
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2613-2617. PubMed ID: 30256068
[TBL] [Abstract][Full Text] [Related]
13. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme.
Guven DC; Aksun MS; Cakir IY; Kilickap S; Kertmen N
Future Oncol; 2021 Nov; 17(32):4405-4413. PubMed ID: 34409854
[No Abstract] [Full Text] [Related]
14. Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials.
Furtner J; Weller M; Weber M; Gorlia T; Nabors B; Reardon DA; Tonn JC; Stupp R; Preusser M;
Clin Cancer Res; 2022 Jan; 28(1):129-136. PubMed ID: 34667022
[TBL] [Abstract][Full Text] [Related]
15. Temporal muscle thickness as an independent prognostic marker in glioblastoma patients-a systematic review and meta-analysis.
Sadhwani N; Aggarwal A; Mishra A; Garg K
Neurosurg Rev; 2022 Dec; 45(6):3619-3628. PubMed ID: 36350492
[TBL] [Abstract][Full Text] [Related]
16. Impact of temporalis muscle thickness in elderly patients with newly diagnosed glioblastoma treated with radio or radio-chemotherapy.
Pasqualetti F; Gabelloni M; Gonnelli A; Faggioni L; Cantarella M; Montrone S; Gadducci G; Giannini N; Montemurro N; Mattioni R; Perrini P; Morganti R; Cosottini M; Neri E; Paiar F
Radiol Med; 2022 Aug; 127(8):919-924. PubMed ID: 35849309
[TBL] [Abstract][Full Text] [Related]
17. Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis.
Wende T; Kasper J; Prasse G; Glass Ä; Kriesen T; Freiman TM; Meixensberger J; Henker C
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830766
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
[TBL] [Abstract][Full Text] [Related]
19. Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness.
Leone R; Sferruzza G; Calimeri T; Steffanoni S; Conte GM; De Cobelli F; Falini A; Ferreri AJM; Anzalone N
Eur J Radiol; 2021 Oct; 143():109945. PubMed ID: 34492625
[TBL] [Abstract][Full Text] [Related]
20. Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.
Ten Cate C; Huijs SMH; Willemsen ACH; Pasmans RCOS; Eekers DBP; Zegers CML; Ackermans L; Beckervordersandforth J; van Raak EPM; Anten MHME; Hoeben A; Postma AA; Broen MPG
J Neurooncol; 2022 Dec; 160(3):611-618. PubMed ID: 36394717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
